Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Dako recently introduced in the United States its instant quality in situ hybridization, or IQISH, technology, which will reduce the turnaround time for cancer evaluation from two days to three and a half hours. HER2 IQFISH PharmDx, a fluorescence in situ hybridization assay, is the first product approved by the FDA that uses IQISH technology, which is based on the company’s fast IQISH hybridization buffer chemistry.
March 2013—Great Basin Corp., a privately held molecular diagnostics company that develops sample-to-result solutions, has raised $9.5 million in series B funding. The funding was led by private investors and will be used to expand manufacturing, fund research and development, and expand global commercialization efforts.
Tosoh Bioscience’s ST AIA-Pack 25-OH vitamin D assay is for use on most of the company’s AIA system analyzers. Vitamin D measurement is intended as an aid in the determination of vitamin D sufficiency.
Streck’s A1c-Cellular HbA1c control with intact red blood cells is now assayed for Roche Diagnostics’ Cobas c311. A1c-Cellular tests the entire HbA1c procedure, including the lysing of the red blood cell. This step ensures that the entire system—instrument and reagents—is working properly and providing accurate patient results. The control is easy to use; it does not require reconstitution, which reduces the potential for human error.
Eppendorf North America’s epMotion M5073 and P5073 workstations automate and simplify complex, labor-intensive pipetting tasks, saving time and improving the reliability and reproducibility of results.
Thermo Fisher Scientific’s Prelude sample preparation and liquid chromatography (SPLC) system was developed to make analysis of target compounds in complex biological matrices routine for clinical research and forensic toxicology laboratories.
Randox Laboratories’ Acusera 24.7 live online is a Web-based interlaboratory data-management program to complement Acusera third-party quality controls and improve quality control processes within the clinical laboratory, while also helping to interpret QC results.
Inova Diagnostics’ Bio-Flash rapid-response chemiluminescent analyzer is for use by clinical reference and hospital laboratories. Bio-Flash and the company’s Quanta Flash reagents are for autoimmune disease diagnostic testing.
LabCorp recently announced that its biorepository has been accredited by the College of American Pathologists.
Abbott and BioView have entered into an agreement in which BioView will develop automated digital-imaging software for use with Abbott’s molecular diagnostic test to detect rearrangements of the ALK gene in patients with advanced non-small cell lung cancer. The software scans lung tissue specimens that have been tested for the ALK gene rearrangement with Abbott’s fluorescence in situ hybridization technology.
